ChemBioChem Commentary Flags P3 Peptide as Potential Driver of Alzheimer's Toxicity Beyond Amyloid Beta

Raskatov's analysis draws on prior biophysical studies showing P3 forms threadlike fibrils and microscopic clumps in vitro, contradicting the long-held assumption that the peptide remains soluble and inert. The commentary proposes renaming it Amyloid alpha (Aα) to reflect its aggregation propensity and calls for experiments testing whether P3 directly damages neurons or alters Abeta42 toxicity through heterotypic interactions. This reframing challenges the field's near-exclusive focus on beta- and gamma-secretase products.

Decades of clinical failures, including modest effects from lecanemab and donanemab plus risks of brain edema, underscore the limits of Abeta-centric models. Related work in JBC and ACS Chemical Neuroscience has documented P3 in plaques yet dismissed it as a byproduct; Raskatov synthesizes these observations to suggest P3 could seed mixed aggregates or evade current immunotherapies. The result is a hypothesis that the alpha-secretase route, once viewed as protective, may contribute to pathology.

Strengthening the case requires targeted studies: quantitative mass spectrometry of P3 levels in patient CSF, cell-based toxicity assays comparing P3 and Abeta42, and genetic models separating the two pathways. If validated, dual targeting of both peptides could improve trial outcomes within five years.

Next steps include funding for P3-specific antibodies and aggregation inhibitors, plus reanalysis of existing trial data for correlations between residual P3 and cognitive decline. Success hinges on rigorous, powered experiments that distinguish correlation from causation in human tissue.